$6.69
4.70% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
BE0974358906
Symbol
NYXH

Nyxoah SA Stock price

$6.69
-1.15 14.67% 1M
-3.82 36.35% 6M
-1.31 16.38% YTD
-1.54 18.71% 1Y
-3.39 33.63% 3Y
-12.81 65.69% 5Y
-12.81 65.69% 10Y
-12.81 65.69% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.33 4.70%

Key metrics

Basic
Market capitalization
$280.9m
Enterprise Value
$233.3m
Net debt
positive
Cash
$73.6m
Shares outstanding
37.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
55.4 | 17.3
EV/Sales
46.0 | 14.4
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
71.5%
Return on Equity
-52.3%
ROCE
-58.5%
ROIC
-122.4%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$5.1m | $16.2m
EBITDA
$-75.1m | $-76.9m
EBIT
$-78.5m | $-93.0m
Net Income
$-81.4m | $-81.4m
Free Cash Flow
$-66.1m
Growth (TTM | estimate)
Revenue
-14.9% | 209.3%
EBITDA
-47.9% | -18.1%
EBIT
-46.4% | -36.1%
Net Income
-61.3% | -18.2%
Free Cash Flow
-16.2%
Margin (TTM | estimate)
Gross
65.5%
EBITDA
-1,474.8% | -473.8%
EBIT
-1,540.7%
Net
-1,597.5% | -500.9%
Free Cash Flow
-1,296.8%
More
EPS
$-2.2
FCF per Share
$-1.8
Short interest
0.5%
Employees
184
Rev per Employee
$30.0k
Show more

Is Nyxoah SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Nyxoah SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Nyxoah SA forecast:

11x Buy
79%
3x Hold
21%

Analyst Opinions

14 Analysts have issued a Nyxoah SA forecast:

Buy
79%
Hold
21%

Financial data from Nyxoah SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
5.10 5.10
15% 15%
100%
- Direct Costs 1.76 1.76
22% 22%
35%
3.34 3.34
10% 10%
65%
- Selling and Administrative Expenses 39 39
59% 59%
767%
- Research and Development Expense 19 19
54% 54%
379%
-75 -75
48% 48%
-1,473%
- Depreciation and Amortization 3.36 3.36
20% 20%
66%
EBIT (Operating Income) EBIT -79 -79
46% 46%
-1,539%
Net Profit -81 -81
61% 61%
-1,596%

In millions USD.

Don't miss a Thing! We will send you all news about Nyxoah SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nyxoah SA Stock News

Neutral
GlobeNewsWire
2 days ago
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for th...
AD HOC NEWS
2 days ago
Nyxoah SA. / BE0974358906
AD HOC NEWS
2 days ago
Nyxoah SA. / BE0974358906
More Nyxoah SA News

Company Profile

Nyxoah SA engages in the research and development, manufacture and sale of medical devices. It focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Its lead solution platform is based on the Genio system, a validated, user-centered, neurostimulation therapy for obstructive sleep apnea (OSA). The company was founded by Robert Taub and Adi Mashiach on July 15, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Head office Belgium
CEO Olivier Taelman
Employees 184
Founded 2009
Website www.nyxoah.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today